Angle PLC: Researchers Develop Parsortix-Based Process to Efficiently Harvest Cancer Cells From Bone Marrow
|
GUILDFORD, SURREY -- (Marketwired) -- Oct 23, 2017 -- Angle PLC ( AIM:AGL OTCQX:ANPCY For immediate release 23 October 2017 ANGLE plc ("the Company") RESEARCHERS DEVELOP PARSORTIX™-BASED PROCESS TO EFFICIENTLY HARVEST CANCER CELLS FROM BONE MARROW Reactivation of such dormant cells has been implicated in patients with cancer relapse Angle (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, today announces that the Center for Women's Health Tuebingen, Germany, has presented the first report on a successful establishment of a protocol for detecting disseminated tumour cells (DTCs) using cancer patient bone marrow with the Parsortix™ system. The reactivation of dormant DTCs and their release into the bloodstream as circulating tumour cells (CTCs), is the process by which a patient may, sometimes after many years of remission, suffer a relapse through metastasis. There is intense interest in the existence and status of such DTCs that are "hibernating" in the bone marrow. At present, the method of choice for detecting DTCs is a density gradient centrifugation of the bone marrow to enrich for mononuclear cells and then an antibody-based staining for various cell markers. In experiments with spiked cancer cells this procedure was shown to be accompanied by a tremendous reduction of target cells with an average of up to 80% cell loss. This may well be one reason why, in primary breast cancer, DTCs have been found in the bone marrow of only 20-30% of patients. The Tuebingen researchers have shown that their newly established Parsortix™ based protocol allows a recovery of about 80% of input target cells. Furthermore, the Tuebingen team believe that this easy to use method may well be applicable to other (non-blood) body fluids for detection of tumor cells for liquid biopsies. The University Hospital Tuebingen research results were presented in a poster at Europe's leading CTC conference, the Third International Advances in Circulating Tumour Cells (ACTC) Symposium. A copy of the poster is available at https://angleplc.com/library/publications/. ANGLE Founder and Chief Executive, Andrew Newland, commented: Dr. André Koch, Center for Women's Health, Tuebingen commented:
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker) +44 (0)20 7220 0500
Corporate Finance - Adrian Hargrave, Simon Hicks,
Kate Bannatyne
Corporate Broking - Alice Lane, Nikita Jain
WG Partners (Joint Broker) +44 (0) 203 705 9318
Nigel Barnes +44 (0) 203 705 9316
Nigel Birks
FTI Consulting +44 (0) 203 727 1000
Simon Conway, Mo Noonan, Stephanie Cuthbert +1 212 850 5612
Kimberly Ha (US)
For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/ This announcement contains inside information. Notes for editors About ANGLE plc www.angleplc.com ANGLE's cell separation technology is called the Parsortix™ system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in Europe, the United States, Canada, India, China, Japan and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compressibility. The Parsortix™ system has a CE Mark for Europe and FDA authorisation is in process for the United States. ANGLE has established formal collaborations with world-class cancer centres. These Key Opinion Leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. Details are available here http://www.angleplc.com/the-company/collaborators/ The analysis of the cells that can be harvested from patient blood with ANGLE's Parsortix™ system has the potential to help deliver personalised cancer care offering profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer. The global increase in cancer to a 1 in 3 lifetime incidence is set to drive a multi-billion dollar clinical market. The Parsortix™ system is designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug's effectiveness. As well as cancer, the Parsortix™ technology has the potential for deployment with several other important cell types in the future. ANGLE stock trades on the AIM market of the London Stock Exchange under the ticker symbol AGL and in New York on the OTC-QX under the ticker symbol ANPCY. For further information please visit: www.angleplc.com This information is provided by RNS END
For further information ANGLE: ANGLE plc +44 (0) 1483 343434 Andrew Newland Chief Executive Ian Griffiths Finance Director finnCap Ltd (NOMAD and Joint Broker) +44 (0)20 7220 0500 Corporate Finance Adrian Hargrave Simon Hicks Kate Bannatyne Corporate Broking Alice Lane Nikita Jain WG Partners (Joint Broker) +44 (0) 203 705 9318 +44 (0) 203 705 9316 Nigel Barnes Nigel Birks FTI Consulting +44 (0) 203 727 1000 +1 212 850 5612 Simon Conway Mo Noonan Stephanie Cuthbert Kimberly Ha (US) |